GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Treasury Stock

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Treasury Stock : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Calliditas Therapeutics AB's treasury stock for the quarter that ended in Dec. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Calliditas Therapeutics AB Treasury Stock Historical Data

The historical data trend for Calliditas Therapeutics AB's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Treasury Stock Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Treasury Stock
Get a 7-Day Free Trial Premium Member Only - - - - -

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Calliditas Therapeutics AB Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Headlines